Eupraxia Pharmaceuticals (EPRX) Q1 2026 earnings summary

Executive summary

• Positive nine-month tissue health and symptom data reported for highest dose cohort in Phase 1b/2a RESOLVE trial for EoE.

• Robust response observed after 36 weeks following a single treatment of EP-104GI.

• Recent $63.2 million public offering completed to fund further clinical trials and development.

Financial highlights

• Net loss of $12.7 million for Q1 2026, compared to $6.8 million in Q1 2025, mainly due to increased R&D and administrative costs.

• Cash and cash equivalents of $58.5 million and short-term investments of $80.4 million as of March 31, 2026.

• Well-capitalized with over $140 million in cash, expected to fund operations into H2 2028.

Outlook and guidance

• Existing cash reserves and anticipated warrant exercises expected to fund operations into the second half of 2028.

• Plans to accelerate clinical programs in new GI indications leveraging Diffusphere technology.